What is Canbridge Pharmaceuticals Selling, General, & Admin. Expense?
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Canbridge Pharmaceuticals's selling, general, & admin. expense for the
six
months ended in Dec. 2024 was HK$72.19 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2024 was HK$153.41 Mil.
Canbridge Pharmaceuticals Selling, General, & Admin. Expense Historical Data
The historical data trend for Canbridge Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Canbridge Pharmaceuticals Selling, General, & Admin. Expense Chart
Competitive Comparison of Canbridge Pharmaceuticals's Selling, General, & Admin. Expense
For the Biotechnology subindustry, Canbridge Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's Selling, General, & Admin. Expense falls into.
Canbridge Pharmaceuticals Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$153.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canbridge Pharmaceuticals (HKSE:01228) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Canbridge Pharmaceuticals Selling, General, & Admin. Expense Related Terms
Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Canbridge Pharmaceuticals Inc is a biotechnology company committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. Its differentiated drug portfolio comprises both approved drugs and a pipeline of assets, targeting prevalent rare disease indications that have unmet needs and market potential. The group's approved products include Hunterase (CAN101) for the treatment of MPS II and Livmarli for the treatment of ALGS. The various other drug candidates in its development pipeline include CAN 103, CAN 107, CAN 104, CAN 105, and CAN 204, spanning biologics, small molecules, and gene therapy, targeting prevalent rare diseases and oncology indications. Geographically, it derives revenue from Chinese Mainland and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01228 has been successfully added to your 